1. 毕业设计（论文）的内容和要求

内容：探讨mir-196a2基因 (rs11614913)多态性与肾细胞癌的关系，并将与肾细胞癌相关的一些因素用一些特殊的方案排查出来。

要求：一般采用分子流行病学病例-对照研究方法，其中包括若干名确诊为肾细胞癌的患者和若干名没有患肿瘤的正常人并且两组人的年龄相似。

采用taqman方法进行基因分型并分析mir-196a2的基因位点(rs11614913)多态性与肾细胞癌易感性的关系。

2. 参考文献

[1]Jemal, A. et al. Cancer statistics, 2008. CA Cancer J Clin 58, 71-96,doi:10.3322/CA.2007.0010CA.2007.0010 [pii] (2008). [2]Devesa, S. S. et al. Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control 1, 133-141 (1990). [3]Verhoest, G. et al. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol 51, 1298-1304; discussion 1304-1295, doi:S0302-2838(06)01566-1 [pii]10.1016/j.eururo.2006.11.056 (2007). [4]Zambrano,N. R., Lubensky, I. A., Merino, M. J., Linehan, W. M. Walther, M. M. Histopathology and molecular genetics of renal tumors toward unification of a classification system. J Urol 162, 1246-1258, doi:S0022-5347(05)68259-6 [pii] (1999). [5]Chow, W. H. Devesa, S. S. Contemporary epidemiology of renal cell cancer. Cancer J 14, 288-301, doi:10.1097/PPO.0b013e318186762800130404-200809000-00003 [pii] (2008). [6]Mathew, A., Devesa, S. S., Fraumeni, J. F., Jr. Chow, W. H. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 11, 171-178 (2002). [7]Dhote, R., Pellicer-Coeuret, M., Thiounn, N., Debre, B. Vidal-Trecan, G. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 86, 20-27, doi:bju708 [pii] (2000). [8]Godschalk, R. W., Feldker, D. E., Borm, P. J., Wouters, E. F. van Schooten, F. J. Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev 11, 790-793 (2002). [9]Rundle, A. et al. The association between benzo[a]pyrene-DNA adducts and body massindex, calorie intake and physical activity. Biomarkers 12, 123-132, doi:10.1080/13547500601010418 (2007). [10] Yang, L., Parkin, D. M., Ferlay, J., Li, L. Chen, Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14, 243-250, doi:14/1/243 [pii] (2005). [11] Calin,G. A. Croce, C. M. MicroRNA signatures in human cancers. Nat Rev Cancer 6, 857-866, doi:nrc1997 [pii]10.1038/nrc1997 (2006). [12] Guo, H., Ingolia, N. T., Weissman, J. S. Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840, doi:10.1038/nature09267nature09267 [pii] (2010). [13] Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233, doi:10.1016/j.cell.2009.01.002S0092-8674(09)00008-7 [pii] (2009). [14] Calin, G. A. et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A 101, 11755-11760, doi:10.1073/pnas.04044321010404432101 [pii] (2004). [15] Xie, X. et al. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 434, 338-345, doi:nature03441 [pii]10.1038/nature03441 (2005). [16] Berezikov, E. et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120, 21-24, doi:S0092867404012565 [pii]10.1016/j.cell.2004.12.031 (2005). [17] Poy, M. N. et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432, 226-230, doi:nature03076 [pii]10.1038/nature03076 (2004). [18] Johnston, R. J. Hobert, O. A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. Nature 426, 845-849, doi:10.1038/nature02255nature02255 [pii] (2003). [19] Brennecke, J., Hipfner, D. R., Stark, A., Russell, R. B. Cohen, S. M. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113, 25-36, doi:S0092867403002319 [pii] (2003). [20] Hu, Z. et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118, 2600-2608, doi:10.1172/JCI34934 (2008). [21] Hu, Z.et al. Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med 183, 641-648, doi:10.1164/rccm.201005-0717OC201005-0717OC [pii] (2011). [22] Christensen,B.C.et al. Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin Cancer Res 16, 3713-3720, doi:10.1158/1078-0432.CCR-10-06571078-0432.CCR-10-0657 [pii] (2010). [23] Duan, R., Pak, C. Jin, P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 16, 1124-1131, doi:ddm062 [pii] 10.1093/hmg/ddm062 (2007). [24] Srivastava, K., Srivastava, A. Mittal, B. Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet 55, 495-499, doi:10.1038/jhg.2010.54jhg201054 [pii] (2010). [25] Qi, P. et al. Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol 71, 621-626, doi:10.1016/j.humimm.2010.02.017S0198-8859(10)00060-1 [pii] (2010). [26] Peng, S. et al. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci 55, 2288-2293, doi:10.1007/s10620-009-1007-x (2010). [27] Liu, Z. et al. Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck. Cancer 116, 4753-4760, doi:10.1002/cncr.25323 (2010). [28] Kim, M. J., Yoo, S. S., Choi, Y. Y. Park, J. Y. A functional polymorphism in the pre-microRNA-196a2 and the risk of lung cancer in a Korean population. Lung Cancer 69, 127-129, doi:10.1016/j.lungcan.2010.04.015S0169-5002(10)00202-3 [pii] (2010). [29] Dou, T. et al. A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. J Cancer Res Clin Oncol 136, 1853-1859, doi:10.1007/s00432-010-0844-5 (2010). [30] Tian, T. et al. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18, 1183-1187, doi:10.1158/1055-9965.EPI-08-08141055-9965.EPI-08-0814 [pii] (2009). [31] Hu, Z. et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 30, 79-84, doi:10.1002/humu.20837 (2009). [32] Hoffman, A. E. et al. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 69, 5970-5977, doi:10.1158/0008-5472.CAN-09-02360008-5472.CAN-09-0236 [pii] (2009). [33] Chu, H. et al. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 6, e18108, doi:10.1371/journal.pone.0018108 (2011). [34] Zhu, L. et al. A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol 31, 350-354, doi:10.1089/dna.2011.1348 (2012). [35] Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592, doi:mdl498 [pii]10.1093/annonc/mdl498 (2007). [36] Thoenes, W., Storkel, S. Rumpelt, H. J. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.Pathol Res Pract 181,125-143,doi:S0344-0338(86)80001-2 [pii]10.1016/S0344-0338(86)80001-2 (1986). [37] Ljungberg, B. Prognostic factors in renal cell carcinoma. Urologe A 43 Suppl 3, S119-120, doi:10.1007/s00120-004-0594-6 (2004). [38] Bray, F., Sankila, R., Ferlay, J. Parkin, D. M. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38, 99-166, doi:S0959804901003501 [pii] (2002). [39] Skinner, D. G., Colvin, R. B., Vermillion, C. D., Pfister, R. C. Leadbetter, W. F. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28, 1165-1177 (1971). [40] Linehan, W. M., Lerman, M. I. Zbar, B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273, 564-570 (1995). [41] Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S. Calin, G. A. MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer 9, 293-302, doi:10.1038/nrc2619nrc2619 [pii] (2009). [42] Lee, K. H. et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp Cell Res 315, 2529-2538, doi:10.1016/j.yexcr.2009.06.001S0014-4827(09)00261-4 [pii] (2009). [43] Croce, C. M. Oncogenes and cancer. N Engl J Med 358, 502-511, doi:10.1056/NEJMra072367358/5/502 [pii] (2008).

3. 毕业设计（论文）进程安排

1、（2016年1月15日前）：阅读相关文献，广泛查阅资料，完善课题研究方案并撰写开题报告； 2、（2016年2月15日前）：选择合适的病例人群和对照人群作为研究对象，并对研究就对象进行资料收集，建立相应的电子数据库； 3、、（2016年4月10日前）：完成基因组DNA提取及基因片段的扩增与分型； 4、（2016年5月1日前）：对病例与对照的一般情况及临床资料分析；对miR-196a2基因（rs11614913）多态位点分析。

5、（2016年6月5日前）：撰写毕业论文。